Journal article
Targeted therapeutic mild hypercapnia after cardiac arrest: A phase II multi-centre randomised controlled trial (the CCC trial)
GM Eastwood, AG Schneider, S Suzuki, L Peck, H Young, A Tanaka, J Mårtensson, S Warrillow, S McGuinness, R Parke, E Gilder, L Mccarthy, P Galt, G Taori, S Eliott, T Lamac, M Bailey, N Harley, D Barge, CL Hodgson Show all
Resuscitation | Published : 2016
Abstract
Background: In intensive care observational studies, hypercapnia after cardiac arrest (CA) is independently associated with improved neurological outcome. However, the safety and feasibility of delivering targeted therapeutic mild hypercapnia (TTMH) for such patients is untested. Methods: In a phase II safety and feasibility multi-centre, randomised controlled trial, we allocated ICU patients after CA to 24 h of targeted normocapnia (TN) (PaCO2 35-45 mmHg) or TTMH (PaCO2 50-55 mmHg). The primary outcome was serum neuron specific enolase (NSE) and S100b protein concentrations over the first 72 h assessed in the first 50 patients surviving to day three. Secondary end-points included global mea..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
The trial was supported by the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS Clinical Trials Group). Funding support was also received from the Anaesthesia Intensive Care Trust Fund (Austin Hospital, Melbourne); Intensive Care Foundation; Ambulance Victoria; Austin Medical Research Foundation; and, Green Lane Research and Educational Fund Board, Auckland City Hospital. Laerdal Foundation Project Grant 2015. Funding bodies did not have input into the design, management or reporting of the trial.